Form 4: Sangamo Executive Reports Routine RSU Tax Withholding

SVP-Chief Development Officer Nathalie Dubois-Stringfellow reported the disposition of shares for mandatory tax withholding related to restricted stock unit vesting.

Summary

• Nathalie Dubois-Stringfellow, SVP-Chief Development Officer of Sangamo Therapeutics, Inc., reported two dispositions of common stock.
• These dispositions were solely for mandatory tax withholding purposes related to the vesting of Restricted Stock Units (RSUs) under the Issuer's Amended and Restated 2018 Equity Incentive Plan.
• The transactions are not discretionary trades by the reporting person in the open market or otherwise.
• On February 24, 2026, 2,063 shares were surrendered at a price of $0.4725 per share.
• On February 25, 2026, 12,354 shares were surrendered at a price of $0.47 per share.
• Following these transactions, Dubois-Stringfellow beneficially owns 678,711 shares of common stock.
• Remaining RSU grants will vest in future installments, subject to continuous service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine, non-discretionary transaction related to executive compensation and mandatory tax obligations.

Positives

• The executive continues to hold a significant number of shares (678,711), indicating ongoing alignment with shareholder interests.
• The vesting of RSUs demonstrates the company's ongoing equity compensation program for key executives.

Negatives

• No specific negatives are indicated by this routine tax withholding transaction.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

Future vesting installments of Restricted Stock Units are scheduled, subject to the reporting person's continuous service with the company.

Management Comments

• This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

Industry Context

StockSavvy.ai notes that routine Form 4 filings for tax-related dispositions of equity awards are common across the biotechnology and pharmaceutical industries, reflecting standard executive compensation practices and the mechanics of RSU vesting.

Comparison to Industry Standards

• The practice of surrendering shares for tax withholding upon RSU vesting is a standard mechanism for equity compensation, consistent with practices observed at comparable biotech firms such as CRISPR Therapeutics (CRSP) or Editas Medicine (EDIT).
• The reported share prices of $0.4725 and $0.47 are specific to Sangamo Therapeutics and reflect its current market valuation, which would be compared against peer companies' stock performance and RSU grant values in a broader compensation analysis.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine, non-discretionary transaction. It slightly reduces the executive's direct beneficial ownership but is offset by the ongoing vesting schedule.
• Employees: Reflects standard equity compensation practices for executives.

Next Steps

• Remaining 90,000 shares from the February 25, 2025 RSU grant will vest in 8 successive equal quarterly installments after February 25, 2026.
• Vesting of all RSU grants is subject to the Reporting Person's Continuous Service through each vesting date.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Executive Compensation, Nathalie Dubois-Stringfellow